El Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertib

Menarini, Stemline and Ryvu reported initial Phase II JASPIS-01 data showing clinical activity and a manageable safety profile for dapolsertib monotherapy in heavily pretreated patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma. The study population had received a median of four prior treatment lines; 53% had previously received CAR-T therapy and 60% CD3×CD20 bispecific antibodies. The investigational drug, given at 125 mg orally once daily on days 1–14 of 21-day cycles, is not approved; the data are scheduled for presentation at ASH on December 13, 2026.

Analysis

The key equity read-through is to Ryvu, but the asset’s economics are not disclosed here: Menarini funds development and holds global rights, so clinical de-risking may create royalty or milestone value without translating one-for-one into near-term revenue. Do not capitalize the press release as proof of meaningful commercial value. It omits cohort size, response rate, response durability, follow-up, and adverse-event detail—the data needed to distinguish a signal from a clinically differentiated therapy.

The December 13 ASH poster is the next identifiable catalyst, with a roughly one-month window for investors to reassess the signal. In the 1–3 month horizon, durability and activity by prior CAR-T/bispecific exposure matter more than a pooled response headline. Longer term, a credible post-CAR-T/bispecific option could broaden treatment choices in aggressive B-cell lymphoma and pressure incumbent salvage approaches at the margin; this is not yet evidence of displacement. Combination data with glofitamab are a separate cohort and should not be conflated with monotherapy results.

Contrarian point: the unmet need is large, but it can encourage investors to overvalue any early activity in a heavily pretreated population. Conversely, an oral agent with manageable reported tolerability could be strategically useful if responses prove durable and reproducible. No direct read-through to BioNTech or Exelixis follows from their mention as Ryvu collaborators; the article provides no change to either partnership’s economics or outlook.

Key Decisions for Investors

• Treat RVU (Warsaw) as a clinical-event watch, not a confirmed fundamental re-rating. Before taking exposure, verify the ASH abstract for patient count, ORR/CR, duration of response, follow-up, grade 3+ toxicity, and outcomes specifically after CAR-T and bispecific therapy.
• Avoid chasing the announcement alone. If the poster shows a credible, durable signal across the most relevant post-CAR-T/bispecific patients, consider a small, event-sized RVU position; keep sizing modest because the economics to Ryvu and the eventual addressable market are not specified.
• Falsify the bullish thesis if the apparent activity is limited to transient responses, the evaluable cohort is small, or safety limits sustained dosing. Reassess on subsequent JASPIS-01 updates, including the distinct glofitamab combination cohort, rather than extrapolating from preliminary monotherapy data.
• No trade implication for BNTX or EXEL from this item: their names occur only in Ryvu’s partnership background, with no reported operational or financial change.